Jun Luo
About
Jun Luo is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Cancer Research.
According to data from OpenAlex, Jun Luo has authored 146 papers receiving a total of 9.4k indexed citations (citations by other indexed papers that have themselves been cited), including 97 papers in Pulmonary and Respiratory Medicine, 56 papers in Molecular Biology and 38 papers in Cancer Research. Recurrent topics in Jun Luo's work include Prostate Cancer Treatment and Research (94 papers), Hormonal and reproductive studies (25 papers) and Prostate Cancer Diagnosis and Treatment (21 papers). Jun Luo is often cited by papers focused on Prostate Cancer Treatment and Research (94 papers), Hormonal and reproductive studies (25 papers) and Prostate Cancer Diagnosis and Treatment (21 papers). Jun Luo collaborates with scholars based in United States, China and United Kingdom. Jun Luo's co-authors include William B. Isaacs, Emmanuel S. Antonarakis, Changxue Lu, Rong Hu, Angelo M. De Marzo, Thomas A. Dunn, Charles M. Ewing, Samuel R. Denmeade, Mario A. Eisenberger and Michael A. Carducci and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Investigation and Nature Communications.
In The Last Decade
Jun Luo
141 papers receiving 9.3k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Jun Luo United States | 50 | 5.7k | 4.6k | 3.3k | 1.7k | 1.2k | 146 | 9.4k | ||
| Ilsa M. Coleman United States | 46 | 4.0k 0.7× | 3.8k 0.8× | 2.2k 0.7× | 2.2k 1.3× | 802 0.6× | 111 | 7.8k | ||
| Christopher P. Evans United States | 58 | 4.9k 0.9× | 5.1k 1.1× | 3.6k 1.1× | 1.8k 1.1× | 731 0.6× | 250 | 10.3k | ||
| Eva Corey United States | 50 | 3.9k 0.7× | 3.8k 0.8× | 1.8k 0.6× | 3.3k 1.9× | 412 0.3× | 194 | 7.9k | ||
| Srinivasan Yegnasubramanian United States | 52 | 3.8k 0.7× | 6.3k 1.4× | 2.7k 0.8× | 1.6k 1.0× | 412 0.3× | 166 | 9.9k | ||
| Colm Morrissey United States | 48 | 2.9k 0.5× | 3.8k 0.8× | 2.5k 0.8× | 2.2k 1.3× | 317 0.3× | 146 | 7.2k | ||
| Tapio Visakorpi Finland | 67 | 7.1k 1.2× | 9.8k 2.1× | 7.0k 2.2× | 3.1k 1.8× | 1.3k 1.1× | 234 | 16.4k | ||
| Haiyen E. Zhau United States | 51 | 2.7k 0.5× | 3.9k 0.9× | 1.8k 0.5× | 2.8k 1.7× | 259 0.2× | 131 | 8.0k | ||
| Robert E. Reiter United States | 58 | 7.6k 1.3× | 3.6k 0.8× | 2.0k 0.6× | 2.8k 1.6× | 388 0.3× | 234 | 12.0k | ||
| Generoso Bevilacqua Italy | 49 | 2.1k 0.4× | 5.5k 1.2× | 1.9k 0.6× | 3.8k 2.3× | 886 0.7× | 283 | 10.3k | ||
| Ingrid A. Mayer United States | 46 | 3.3k 0.6× | 5.0k 1.1× | 3.4k 1.0× | 6.0k 3.5× | 321 0.3× | 210 | 12.0k |
Countries citing papers authored by Jun Luo
Since
Specialization
Citations
This map shows the geographic impact of Jun Luo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jun Luo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jun Luo more than expected).
Fields of papers citing papers by Jun Luo
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Jun Luo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jun Luo. The network helps show where Jun Luo may publish in the future.
Co-authorship network of co-authors of Jun Luo
This figure shows the co-authorship network connecting the top 25 collaborators of Jun Luo. A scholar is included among the top collaborators of Jun Luo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jun Luo. Jun Luo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Kanayama, Mayuko, Émeline Colomba, Sarah M. Nielsen, et al.. (2025). Case series exploring hormonal sensitivity in prostate cancer patients harboring the germline African-ancestry HOXB13 X285K variant. Prostate Cancer and Prostatic Diseases.
2.
Marshall, Catherine H., Stamatina Fragkogianni, Lukasz P. Gondek, et al.. (2025). Germline DNA Repair Gene Mutations and Clonal Hematopoiesis (CH) in 24,849 Patients with BRCA-Associated Cancers. Cancers. 17(9). 1432–1432.
3.
Halabi, Susan, Joseph J. Park, David M. Nanus, et al.. (2024). The Impact of Circulating Tumor Cell HOXB13 RNA Detection in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Abiraterone or Enzalutamide. Clinical Cancer Research. 30(6). 1152–1159.
4.
Kyriakopoulos, Christos E., Yu‐Hui Chen, Robert Jeraj, et al.. (2024). Cabazitaxel with abiraterone versus abiraterone alone randomized trial for extensive disease following docetaxel: The CHAARTED2 trial of the ECOG-ACRIN Cancer Research Group (EA8153).. Journal of Clinical Oncology. 42(17_suppl). LBA5000–LBA5000.
5.
Marshall, Catherine H., Lukasz P. Gondek, Changxue Lu, et al.. (2024). Association of PARP inhibitor treatment on the prevalence and progression of clonal hematopoiesis in patients with advanced prostate cancer. The Prostate. 84(10). 954–958.
6.
Kanayama, Mayuko, Yidong Chen, Changxue Lu, et al.. (2023). Clinical and Functional Analyses of an African-ancestry Gain-of-function HOXB13 Variant Implicated in Aggressive Prostate Cancer. European Urology Oncology. 7(4). 751–759.
7.
Patterson, Jesse C., Andreas Varkaris, Peter J.P. Croucher, et al.. (2022). Plk1 Inhibitors and Abiraterone Synergistically Disrupt Mitosis and Kill Cancer Cells of Disparate Origin Independently of Androgen Receptor Signaling. Cancer Research. 83(2). 219–238.
8.
Wang, Keliang, Jie Luo, Shuyuan Yeh, et al.. (2020). The MAO inhibitors phenelzine and clorgyline revert enzalutamide resistance in castration resistant prostate cancer. Nature Communications. 11(1). 2689–2689.
9.
Mangold, Leslie A., W. Nathaniel Brennen, Kenneth J. Pienta, et al.. (2020). A novel method for detection of exfoliated prostate cancer cells in urine by RNA in situ hybridization. Prostate Cancer and Prostatic Diseases. 24(1). 220–232.
10.
Kawamura, Norihiko, Keisuke Nimura, Kotaro Saga, et al.. (2019). SF3B2-Mediated RNA Splicing Drives Human Prostate Cancer Progression. Cancer Research. 79(20). 5204–5217.
11.
Paller, Channing J., James R. Eshleman, Samuel R. Denmeade, et al.. (2019). A pilot study of prostate‐specific membrane antigen (PSMA) dynamics in men undergoing treatment for advanced prostate cancer. The Prostate. 79(14). 1597–1603.
12.
Guedes, Liana B., Carlos L. Morais, Fawaz Almutairi, et al.. (2016). Analytic Validation of RNA In Situ Hybridization (RISH) for AR and AR-V7 Expression in Human Prostate Cancer. Clinical Cancer Research. 22(18). 4651–4663.
13.
Yu, Shu-Han, Qizhi Zheng, David Esopi, et al.. (2015). A Paracrine Role for IL6 in Prostate Cancer Patients: Lack of Production by Primary or Metastatic Tumor Cells. Cancer Immunology Research. 3(10). 1175–1184.
14.
Zeng, Yu, Dong Gao, Takumi Shiraishi, et al.. (2013). Stress-Response Protein RBM3 Attenuates the Stem-like Properties of Prostate Cancer Cells by Interfering with CD44 Variant Splicing. Cancer Research. 73(13). 4123–4133.
15.
Isaacs, John T., Lizamma Antony, Susan L. Dalrymple, et al.. (2012). Tasquinimod Is an Allosteric Modulator of HDAC4 Survival Signaling within the Compromised Cancer Microenvironment. Cancer Research. 73(4). 1386–1399.
16.
Hu, Rong, Changxue Lu, Elahe A. Mostaghel, et al.. (2012). Distinct Transcriptional Programs Mediated by the Ligand-Dependent Full-Length Androgen Receptor and Its Splice Variants in Castration-Resistant Prostate Cancer. Cancer Research. 72(14). 3457–3462.
17.
Zhang, Chunpeng, Liguo Wang, Dayong Wu, et al.. (2011). Definition of a FoxA1 Cistrome That Is Crucial for G1 to S-Phase Cell-Cycle Transit in Castration-Resistant Prostate Cancer. Cancer Research. 71(21). 6738–6748.
18.
Ribas, Judit, Xiaohua Ni, Michael C. Haffner, et al.. (2009). miR-21: An Androgen Receptor–Regulated MicroRNA that Promotes Hormone-Dependent and Hormone-Independent Prostate Cancer Growth. Cancer Research. 69(18). 7165–7169.
19.
Hu, Rong, Thomas A. Dunn, Shuanzeng Wei, et al.. (2008). Ligand-Independent Androgen Receptor Variants Derived from Splicing of Cryptic Exons Signify Hormone-Refractory Prostate Cancer. Cancer Research. 69(1). 16–22.
20.
Luo, Jun. (2002). Three dimensional culture of animal cells in a fibrous bed bioreactor /. OhioLink ETD Center (Ohio Library and Information Network).
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Ilsa M. Coleman Breakdown of academic impact, for papers by Christopher P. Evans Breakdown of academic impact, for papers by Eva Corey Breakdown of academic impact, for papers by Srinivasan Yegnasubramanian Breakdown of academic impact, for papers by Colm Morrissey Breakdown of academic impact, for papers by Tapio Visakorpi Breakdown of academic impact, for papers by Haiyen E. Zhau Breakdown of academic impact, for papers by Robert E. Reiter Breakdown of academic impact, for papers by Generoso Bevilacqua Breakdown of academic impact, for papers by Ingrid A. Mayer